Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.
| Author | |
|---|---|
| Abstract |
:
Middle East respiratory syndrome (MERS) is a severe respiratory illness with an overall mortality of 35%. There is no licensed or proven treatment. Passive immunotherapy approaches are being developed to prevent and treat several human medical conditions where alternative therapeutic options are absent. We report the safety of a fully human polyclonal IgG antibody (SAB-301) produced from the hyperimmune plasma of transchromosomic cattle immunised with a MERS coronavirus vaccine. |
| Year of Publication |
:
2018
|
| Journal |
:
The Lancet. Infectious diseases
|
| Date Published |
:
2018
|
| ISSN Number |
:
1473-3099
|
| URL |
:
http://linkinghub.elsevier.com/retrieve/pii/S1473-3099(18)30002-1
|
| DOI |
:
10.1016/S1473-3099(18)30002-1
|
| Short Title |
:
Lancet Infect Dis
|
| Download citation |
